Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:30 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 4,220 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-04603629, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more
Conditions
Cleft Palates
Interventions
Unasyn, saline solution
Drug · Other
Lead sponsor
Joseph Losee
Other
Eligibility
3 Months to 18 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Conditions
Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
13
States / cities
Jacksonville, Florida • Alpharetta, Georgia • Macon, Georgia + 9 more
Conditions
Multiple Sclerosis
Interventions
mRNA-1195, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Boston, Massachusetts • Farmington Hills, Michigan • Ozark, Missouri + 5 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Gingivitis
Interventions
AMY-101, Water for injection
Drug · Other
Lead sponsor
Amyndas Pharmaceuticals S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of SUNPG1623

NCT02980692
Conditions
Active Psoriatic Arthritis
Interventions
SUNPG1623 I, SUNPG1623 II, SUNPG1623 III, SUNPG1623 IV, PLACEBO
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Conditions
Upper Limb Spasticity
Interventions
DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
26
States / cities
Downey, California • Fountain Valley, California • Long Beach, California + 22 more
Completed Phase 3 Interventional Results available

ACTH for Fatigue in Multiple Sclerosis Patients

NCT02315872
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTH, Placebo
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 105 Years
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
205
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more
Conditions
Retinal Detachment
Interventions
denufosol tetrasodium (INS37217) Intravitreal Injection
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
33
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 29 more
Conditions
Crohn Disease
Interventions
JNJ-64304500, Placebo, Adalimumab, Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Evansville, Indiana
Enrolling by invitation Phase 2 Interventional

TRACK-TBI Precision Medicine Part 3 - Option II

NCT06790095
Conditions
Traumatic Brain Injury
Interventions
Cyclosporine (CsA), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
San Francisco, California • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 1 more
Completed Phase 2 Interventional Results available

The Role of Hormones in Postpartum Mood Disorders

NCT00001481
Conditions
Postpartum Depression
Interventions
Estradiol, Placebo, Progesterone, leuprolide acetate
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Upper Limb Essential Tremor
Interventions
AGN-151607-DP, Placebo for AGN-151607-DP
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Fresno, California • Fullerton, California + 16 more
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg, Golimumab 50 mg
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Roseville, California + 55 more
Conditions
Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
Interventions
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Conditions
Essential Tremor
Interventions
Botulinum toxin, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Hip Fracture, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Osteoarthritis of the Knees
Interventions
CX-011
Drug
Lead sponsor
CarthroniX, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Autoimmune Hepatitis
Interventions
zetomipzomib, placebo, zetomipzomib in open-label extension
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more
Conditions
Pain Assessment, Quality of Life (QOL), Analgesic Use
Interventions
Supplemental Postoperative Bupivacaine, Placebo Injection
Drug
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York